Patrick Altmann

Vienna, 1090, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 54 publications

Building interprofessional identity in neurology with interactive interprofessional learning: a randomized controlled trial.

Building interprofessional identity in neurology with interactive interprofessional learning: a randomized controlled trial.

Journal: BMC medical education

Published: February 13, 2025

A randomized controlled pilot study investigating adherence to blood pressure diaries with personal pictures in stroke follow-up care.

A randomized controlled pilot study investigating adherence to blood pressure diaries with personal pictures in stroke follow-up care.

Journal: Wiener klinische Wochenschrift

Published: January 01, 2025

Retinal thinning differentiates treatment effects in relapsing multiple sclerosis below the clinical threshold.

Retinal thinning differentiates treatment effects in relapsing multiple sclerosis below the clinical threshold.

Journal: Annals of clinical and translational neurology

Published: October 19, 2024

Association of Disease-Modifying Treatment With Outcome in Patients With Relapsing Multiple Sclerosis and Isolated MRI Activity.

Association of Disease-Modifying Treatment With Outcome in Patients With Relapsing Multiple Sclerosis and Isolated MRI Activity.

Journal: Neurology

Published: August 28, 2024

Treating to target in multiple sclerosis: Do we know how to measure whether we hit it?

Treating to target in multiple sclerosis: Do we know how to measure whether we hit it?

Journal: European journal of neurology

Published: August 12, 2024

Retinal layer thinning for monitoring disease-modifying treatment in relapsing multiple sclerosis-Evidence for applying a rebaselining concept.

Retinal layer thinning for monitoring disease-modifying treatment in relapsing multiple sclerosis-Evidence for applying a rebaselining concept.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: August 07, 2024

Investigation of serum neurofilament light chain as a biomarker in Fabry disease.

Investigation of serum neurofilament light chain as a biomarker in Fabry disease.

Journal: Scientific reports

Published: July 24, 2024

Cost-effectiveness of the Floodlight® MS app in Austria. Unlocking the mystery of costs and outcomes of a digital health application for patients with multiple sclerosis.

Cost-effectiveness of the Floodlight® MS app in Austria. Unlocking the mystery of costs and outcomes of a digital health application for patients with multiple sclerosis.

Journal: Digital health

Published: June 26, 2024

Immunophenotyping in routine clinical practice for predicting treatment response and adverse events in patients with MS.

Immunophenotyping in routine clinical practice for predicting treatment response and adverse events in patients with MS.

Journal: Frontiers in neurology

Published: February 20, 2024

Real-world performance of plasma p-tau181 in a heterogeneous memory clinic cohort.

Real-world performance of plasma p-tau181 in a heterogeneous memory clinic cohort.

Journal: Annals of clinical and translational neurology

Published: December 27, 2023

Serum neurofilament light chain as an early diagnostic biomarker for critical illness polyneuropathy.

Serum neurofilament light chain as an early diagnostic biomarker for critical illness polyneuropathy.

Journal: Minerva anestesiologica

Published: October 18, 2023

Correction: Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR).

Correction: Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR).

Journal: Journal of neurology

Published: June 05, 2023

Showing 1-12 of 54

Last Updated: 09/26/2026